Skip to main content
Ensol Biosciences Inc. logo

Ensol Biosciences Inc. — Investor Relations & Filings

Ticker · 140610 ISIN · KR7140610007 KO Manufacturing
Open in API
Filings indexed 255 across all filing types
Latest filing 2026-04-29 Investor Presentation
Country KR South Korea
Listing KO 140610

About Ensol Biosciences Inc.

https://www.ensolbio.co.kr/eng/

Ensol Biosciences Inc. is a biopharmaceutical company focused on developing innovative drugs for diseases with limited or no therapeutic alternatives. The company leverages a bio big data and AI-driven platform for its research and development activities. A core area of its technology involves Protein-Protein Interaction (PPI)-regulating short peptide drugs, which are designed for local injection to maximize therapeutic effects and minimize systemic side effects through high specificity and a short half-life in the blood. The company's pipeline targets a range of medical unmet needs, including degenerative disc disease, osteoarthritis, cancer, and neurodegenerative disorders like Alzheimer's disease. Key clinical-stage assets include E1K for osteoarthritis (preparing for Phase 3) and C1K, an anticancer combination therapy (Phase 1).

Recent filings

Filing Released Lang Actions
기업설명회(IR)개최
Investor Presentation Classification · 90% confidence The document is a Korean announcement detailing the scheduling, participants, agenda, and logistics for a company’s investor relations presentation (기업설명회(IR)). It is not a formal financial report or earnings release, but rather an invitation/notice for an investor presentation event. Therefore, it falls under the “Investor Presentation” category (Code: IP).
2026-04-29 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 92% confidence The document is a formal regulatory notice titled “사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고,” submitted to the Financial Services Commission and Korea Exchange. It details the appointment and dismissal of outside directors, including names, dates, and reasons. This clearly falls under announcements of changes in the company’s board of directors. Therefore, it is classified as Board/Management Information (MANG).
2026-03-26 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 80% confidence The document is a formal regulatory disclosure to the Financial Services Commission/Korea Exchange announcing the grant of stock purchase options (“주식매수선택권 부여”). It details the number of options, exercise period, exercise price, fair value calculation, vesting, and related terms—i.e., a capital change via option issuance rather than a full financial or ESG report. There is no evidence of an earnings release, management change, share repurchase, or proxy materials. The closest FIT is category 28 (SHA) for announcements of new share issues or capital changes. Thus, it is best classified as a Share Issue/Capital Change (SHA).
2026-03-26 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is a disclosure of the resolutions and voting results from the company’s regular shareholders’ meeting held on 2026-03-26. It lists agenda items, vote counts, approval status, and related details. This corresponds to Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-03-26 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share transactions (sales and stock option exercises) of a specific executive (Jeon Nam-deug) of Ensol Biosciences. This is a standard regulatory filing for insider trading/director dealings in the Korean market, which corresponds to the 'Director's Dealing' category.
2026-03-19 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities. This type of filing is a mandatory disclosure for company insiders (directors/executives) to report their personal share transactions or changes in ownership. According to the provided definitions, this corresponds to 'Director's Dealing' (DIRS).
2026-03-19 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.